Company Overview
APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction, high altitude pulmonary oedema and pseudohypoaldosteronism type 1. APEPTICO's SOLNATIDE peptides have been delivered clinical proof of concept in Phase II trials in treatment of pulmonary oedema in mechanically ventilated patients and in patients with primary graft dysfunction following lung transplantation. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.